DaCapo Brainscience develops disease-modifying therapies for neurodegenerative diseases using targeted molecular interventions to halt disease progression. Their approach aims to improve patient outcomes by addressing the underlying mechanisms of conditions such as Alzheimer's and Parkinson's.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's currently lack effective treatments that can halt or reverse disease progression, leading to significant cognitive and motor decline in affected individuals. Existing therapies primarily focus on managing symptoms rather than addressing the underlying molecular mechanisms driving these conditions.
Solution
DaCapo Brainscience is developing disease-modifying therapies for neurodegenerative diseases by targeting specific molecular pathways implicated in disease progression. Their approach aims to intervene at the root cause of conditions like Alzheimer's and Parkinson's, potentially slowing or stopping the advancement of these debilitating illnesses. By focusing on targeted molecular interventions, DaCapo seeks to improve patient outcomes and quality of life by addressing the fundamental mechanisms driving neurodegeneration.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases, their caregivers, and healthcare providers specializing in neurology and geriatric care.
Features
- Targeted molecular interventions designed to halt or reverse neurodegenerative processes.
- Focus on disease-modifying therapies rather than symptomatic treatments.
- Development of treatments for Alzheimer's and Parkinson's disease.